|
US4933168A
(en)
*
|
1975-05-27 |
1990-06-12 |
Syntex Pharmaceuticals International Limited |
Stable, crystalline flunisolide
|
|
MX3864E
(es)
*
|
1975-05-27 |
1981-08-26 |
Syntex Corp |
Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
|
|
GB1571629A
(en)
*
|
1977-11-30 |
1980-07-16 |
Fisons Ltd |
Pharmaceutical compositions containing beclomethasone dipropionate
|
|
IT1121513B
(it)
*
|
1979-05-28 |
1986-04-02 |
Chiesi Farma Spa |
Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
|
|
ATE3774T1
(de)
*
|
1980-05-02 |
1983-06-15 |
Schering Corporation |
Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
|
|
FI63672C
(fi)
*
|
1980-05-19 |
1983-08-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
|
|
KR890000664B1
(ko)
*
|
1981-10-19 |
1989-03-22 |
바리 안소니 뉴우샘 |
미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
|
|
GB8432063D0
(en)
*
|
1984-12-19 |
1985-01-30 |
Riker Laboratories Inc |
Physically modified steroids
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5562608A
(en)
*
|
1989-08-28 |
1996-10-08 |
Biopulmonics, Inc. |
Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
|
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
IL104068A
(en)
*
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
|
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
|
US5683676A
(en)
*
|
1991-12-12 |
1997-11-04 |
Glaxo Group Limited |
Canister containing aerosol formulations containing P134a and particulate medicaments
|
|
EP0616524B1
(fr)
|
1991-12-12 |
1998-10-07 |
Glaxo Group Limited |
Medicaments
|
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US5301664A
(en)
*
|
1992-03-06 |
1994-04-12 |
Sievers Robert E |
Methods and apparatus for drug delivery using supercritical solutions
|
|
AU659328B2
(en)
*
|
1992-06-12 |
1995-05-11 |
Teijin Limited |
Ultrafine powder for inhalation and production thereof
|
|
MX9304585A
(es)
|
1992-07-31 |
1994-03-31 |
Glaxo Group Ltd |
Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
|
|
CA2159498A1
(fr)
*
|
1993-04-01 |
1994-10-13 |
Younsik Cha |
Methode de preparation de medicaments pour traiter les troubles dermiques
|
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
NZ291559A
(en)
*
|
1994-08-09 |
1998-09-24 |
Schering Corp |
Preparation of beclomethasone dipropionate trichloromonofluoromethane clathrate
|
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5863902A
(en)
*
|
1995-01-06 |
1999-01-26 |
Sibia Neurosciences, Inc. |
Methods of treating neurodegenerative disorders using protease inhibitors
|
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
|
US5646130A
(en)
*
|
1995-06-30 |
1997-07-08 |
Ocean University Of Oingdao |
Low molecular weight sulfated polysaccharides and uses thereof
|
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
|
US5700487A
(en)
*
|
1996-03-04 |
1997-12-23 |
The Ohio State University |
Treatment of pulmonary inflammation
|
|
US5958905A
(en)
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
|
US5804585A
(en)
*
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
|
ATE345682T1
(de)
*
|
1996-05-01 |
2006-12-15 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
|
SE9603725D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
New teatment
|
|
US6380222B2
(en)
|
1996-10-11 |
2002-04-30 |
Astrazeneca Ab |
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
|
|
CA2271717A1
(fr)
|
1996-12-12 |
1998-06-18 |
Prolume, Ltd. |
Appareil permettant de detecter et d'identifier des agents infectieux et procede correspondant
|
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
SE9700135D0
(sv)
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
NZ336898A
(en)
|
1997-04-28 |
2001-10-26 |
Texas Biotechnology Corp |
Sulfonamides for treatment of endothelin-mediated disorders
|
|
US6342611B1
(en)
*
|
1997-10-10 |
2002-01-29 |
Cytovia, Inc. |
Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
AU2868099A
(en)
|
1998-02-13 |
1999-08-30 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
|
EP1925320A3
(fr)
|
1998-03-27 |
2008-09-03 |
Prolume, Ltd. |
Luciférases, protéines fluorescentes, acides nucléiques codant pour les luciférases et protéines fluorescentes et leur utilisation pour le diagnostic, le criblage à haut rendement et articles nouveaux
|
|
DE69920473T2
(de)
*
|
1998-07-21 |
2006-02-23 |
Cytovia, Inc., San Diego |
Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
US6677473B1
(en)
|
1999-11-19 |
2004-01-13 |
Corvas International Inc |
Plasminogen activator inhibitor antagonists
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
CN1414965A
(zh)
|
1999-12-31 |
2003-04-30 |
德州生物科技公司 |
调整内皮肽活性的磺酰胺及其衍生物
|
|
US7109315B2
(en)
|
2000-03-15 |
2006-09-19 |
Bruce J. Bryan |
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
|
|
US6596262B2
(en)
|
2001-02-15 |
2003-07-22 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6485707B2
(en)
|
2001-02-15 |
2002-11-26 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6544497B2
(en)
|
2001-02-15 |
2003-04-08 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US20030129203A1
(en)
*
|
2001-08-27 |
2003-07-10 |
Nautilus Biotech S.A. |
Mutant recombinant adeno-associated viruses
|
|
JP2005509616A
(ja)
*
|
2001-10-16 |
2005-04-14 |
センジェント・セラピューティクス・インク |
チロシンホスファターゼに対する有機硫黄阻害剤
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
EP1465882B1
(fr)
*
|
2001-12-21 |
2011-08-24 |
X-Ceptor Therapeutics, Inc. |
Modulateurs heterocycliques de recepteurs nucleaires
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
JP5082033B2
(ja)
|
2001-12-21 |
2012-11-28 |
エグゼリクシス パテント カンパニー エルエルシー |
Ｌｘｒのモジュレーター
|
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
|
US20030199594A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Rasik Shah |
Helium propellant composition for use with aerosols
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
WO2004002476A2
(fr)
|
2002-06-27 |
2004-01-08 |
Health Research, Inc. |
Photosensibilisants fluores associes a des chlores et des bacteriochlores pour la therapie photodynamique
|
|
US7053210B2
(en)
|
2002-07-02 |
2006-05-30 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
EP1539960B1
(fr)
*
|
2002-09-09 |
2010-04-28 |
Hanall Pharmaceutical Co., Ltd. |
Polypeptides modifiés d'interferon alpha résistant aux protéases
|
|
US20050202438A1
(en)
*
|
2002-09-09 |
2005-09-15 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20060020396A1
(en)
*
|
2002-09-09 |
2006-01-26 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
EA200500846A1
(ru)
*
|
2002-11-19 |
2005-12-29 |
Ачиллион Фармасьютикалз, Инк. |
Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
|
|
WO2004060260A2
(fr)
*
|
2002-12-18 |
2004-07-22 |
Glaxo Group Limited |
Systeme d'administration de medicament dote d'un embout buccal a event
|
|
EA009383B1
(ru)
|
2003-03-05 |
2007-12-28 |
Хэлозим, Инк. |
РАСТВОРИМЫЙ ГЛИКОПРОТЕИН ГИАЛУРОНИДАЗЫ (sHASEGP), СПОСОБ ЕГО ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ЕГО СОДЕРЖАЩАЯ
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
MXPA05012281A
(es)
*
|
2003-05-14 |
2006-05-19 |
Torreypines Therapeutics Inc |
Compuestos y uso de los mismos en la modulacion beta amiloide.
|
|
CA2528438A1
(fr)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
Inhibiteurs de p-38
|
|
EP1911754B1
(fr)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de peptidase dipeptidyl
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(fr)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
|
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
US20050261365A1
(en)
|
2004-05-20 |
2005-11-24 |
The Scripps Research Institute |
Transthyretin stabilization
|
|
JP2008503490A
(ja)
*
|
2004-06-17 |
2008-02-07 |
センジェント・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの三置換窒素調節物質
|
|
JP2008505916A
(ja)
*
|
2004-07-09 |
2008-02-28 |
メタバシス・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの酸素／窒素複素環阻害剤
|
|
EP1773348A4
(fr)
|
2004-07-12 |
2009-05-20 |
Idun Pharmaceuticals Inc |
Analogues de tetrapeptide
|
|
WO2006028970A1
(fr)
*
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derives d'inhibiteurs de thiazole et de thiadiazole de tyrosine phosphatases
|
|
ATE531367T1
(de)
|
2004-09-17 |
2011-11-15 |
Whitehead Biomedical Inst |
Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
US7872124B2
(en)
|
2004-12-21 |
2011-01-18 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
CN101189249B
(zh)
|
2005-04-01 |
2013-04-17 |
加利福尼亚大学董事会 |
膦酰基-戊-2-烯-1-基核苷和类似物
|
|
US20060251619A1
(en)
*
|
2005-05-04 |
2006-11-09 |
Gilles Borrelly |
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
|
CN101137655A
(zh)
|
2005-06-17 |
2008-03-05 |
配体药物公司 |
雄激素受体调节剂化合物和方法
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
WO2008051197A2
(fr)
*
|
2005-09-20 |
2008-05-02 |
Mayo Foundation For Medical Education And Research |
Inhibiteurs de toxine botulinique de type petites molécules
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP2428218A1
(fr)
|
2005-10-21 |
2012-03-14 |
Catalyst Biosciences, Inc. |
Protéases modifiées inhibant l'activation de complément
|
|
WO2007076160A2
(fr)
*
|
2005-12-28 |
2007-07-05 |
Acidophil Llc |
Carbamates c-10 de taxanes
|
|
SI2383271T1
(sl)
*
|
2006-03-13 |
2013-10-30 |
Kyorin Pharmaceutical Co., Ltd. |
Aminokinoloni kot inhibitorji gsk-3
|
|
US20080003202A1
(en)
*
|
2006-03-28 |
2008-01-03 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
EP2007373A4
(fr)
*
|
2006-03-29 |
2012-12-19 |
Foldrx Pharmaceuticals Inc |
Inhibition de la toxicité de l'alpha-synucléine
|
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
|
US8383388B2
(en)
|
2006-06-19 |
2013-02-26 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
|
EP2064243A2
(fr)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps monoclonaux humains anti-hlight humain
|
|
WO2008036379A2
(fr)
|
2006-09-21 |
2008-03-27 |
Activx Biosciences, Inc. |
Inhibiteurs de serine hydrolase
|
|
EP2223925A1
(fr)
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinase
|
|
EP2145878A3
(fr)
|
2006-10-09 |
2010-02-24 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinases Aurora
|
|
EP2089359A2
(fr)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinase mapk/erk
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
KR101248252B1
(ko)
|
2006-11-28 |
2013-03-27 |
한올바이오파마주식회사 |
변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
|
|
WO2009070164A1
(fr)
|
2007-11-28 |
2009-06-04 |
University Of Central Florida |
Amélioration de la vigueur par administration de dérivés de pyrimidine
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
AU2007338689A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of C3a receptor and methods of use thereof
|
|
EP2120875B1
(fr)
|
2007-02-11 |
2018-07-11 |
Map Pharmaceuticals Inc. |
Procédé d'administration thérapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
|
|
HRP20110713T1
(hr)
*
|
2007-02-28 |
2011-11-30 |
Conatus Pharmaceuticals |
Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
|
|
EP2203458B1
(fr)
*
|
2007-09-11 |
2011-11-02 |
Kyorin Pharmaceutical Co., Ltd. |
Cyanoaminoquinolones en tant qu'inhibiteurs de gsk-3
|
|
KR101597841B1
(ko)
|
2007-09-12 |
2016-02-26 |
교린 세이야꾸 가부시키 가이샤 |
Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
|
|
ES2488966T3
(es)
|
2007-09-25 |
2014-09-01 |
Takeda Pharmaceutical Company Limited |
Inhibidores de cinasa de tipo Polo
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
NZ585528A
(en)
|
2007-11-21 |
2012-08-31 |
Pharmaxis Ltd |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
|
ES2413504T3
(es)
|
2007-12-21 |
2013-07-16 |
Ligand Pharmaceuticals Inc. |
Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
WO2009128917A2
(fr)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Hyaluronidases modifiées et utilisations pour traiter des maladies et des pathologies associées à l'acide hyaluronique
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
US20110178070A1
(en)
|
2008-06-24 |
2011-07-21 |
Takeda Pharmaceutical Company Limited |
PI3K/mTOR INHIBITORS
|
|
PL2318035T3
(pl)
|
2008-07-01 |
2019-10-31 |
Curemark Llc |
Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
|
|
CN103205407B
(zh)
|
2008-12-09 |
2016-03-16 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
|
EP2373693A4
(fr)
|
2009-01-06 |
2012-04-25 |
Curelon Llc |
Compositions et procédés pour le traitement ou la prévention d'infections orales par e. coli
|
|
CN102300989B
(zh)
|
2009-01-06 |
2015-12-09 |
柯尔朗恩有限责任公司 |
用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
|
|
WO2010102262A1
(fr)
|
2009-03-06 |
2010-09-10 |
Halozyme, Inc. |
Mutants thermosensibles de métalloprotéase matricielle 1 et leurs utilisations
|
|
US8071591B2
(en)
*
|
2009-03-11 |
2011-12-06 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
|
US8669249B2
(en)
|
2009-03-27 |
2014-03-11 |
Takeda Pharmaceutical Company Limited |
Poly (ADP-ribose) polymerase (PARP) inhibitors
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
JP5715625B2
(ja)
|
2009-07-30 |
2015-05-07 |
武田薬品工業株式会社 |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
WO2011041293A1
(fr)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
|
|
WO2011057214A2
(fr)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Composés de modulation de la gamma-sécrétase, procédés pour les identifier, et leurs utilisations
|
|
WO2011069002A1
(fr)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Composés d'organosélénium et leurs utilisations
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
US8648073B2
(en)
*
|
2009-12-30 |
2014-02-11 |
Fochon Pharma, Inc. |
Certain dipeptidyl peptidase inhibitors
|
|
US8802695B2
(en)
|
2010-02-03 |
2014-08-12 |
Takeda Pharmaceutical Company Limited |
Apoptosis signal-regulating kinase 1 inhibitors
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
JP5976100B2
(ja)
|
2011-04-21 |
2016-08-23 |
キュアマーク リミテッド ライアビリティ カンパニー |
神経精神障害の処置のための化合物
|
|
CA2838991A1
(fr)
|
2011-06-23 |
2012-12-27 |
Map Pharmaceuticals, Inc. |
Nouveaux analogues de fluoro-ergoline
|
|
WO2013037482A1
(fr)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
|
|
CA2859173A1
(fr)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Nouveaux derives d'iso-ergoline
|
|
WO2013095708A1
(fr)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Nouveaux composés neuromodulateurs
|
|
IL317266A
(en)
|
2011-12-30 |
2025-01-01 |
Halozyme Inc |
PH20 Polypeptide Variants, Formulations and Uses Thereof
|
|
WO2013134047A2
(fr)
|
2012-03-07 |
2013-09-12 |
The Mclean Hospital Corporation |
Dérivés d'aminoquinoléine et leurs utilisations
|
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
|
JP6182595B2
(ja)
|
2012-05-02 |
2017-08-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP2861562B1
(fr)
|
2012-06-14 |
2018-05-09 |
Mayo Foundation For Medical Education And Research |
Dérivés de pyrazole en tant qu'inhibiteurs de stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
|
WO2014107745A1
(fr)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Métalloprotéases matricielles mutantes sensibles aux métaux et leurs utilisations
|
|
HK1219654A1
(zh)
|
2013-02-22 |
2017-04-13 |
University Of Southern California |
用於治疗眼科疾病和病症的方法
|
|
US9938263B2
(en)
|
2013-03-12 |
2018-04-10 |
The General Hospital Corporation |
Gamma-secretase modulators
|
|
US9732074B2
(en)
|
2013-03-15 |
2017-08-15 |
University Of Southern California |
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
|
|
SG11201509982UA
(fr)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3613418A1
(fr)
|
2014-01-17 |
2020-02-26 |
Ligand Pharmaceuticals, Inc. |
Procédés et compositions de modulation des niveaux d'hormones
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
AU2015259471A1
(en)
|
2014-05-12 |
2016-11-24 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
CA2966423C
(fr)
|
2014-10-31 |
2023-10-24 |
The General Hospital Corporation |
Puissants modulateurs de la secretase gamma
|
|
WO2016094837A2
(fr)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anticorps anti-c10orf54 et leurs utilisations
|
|
EP3237450B1
(fr)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anticorps agonistes anti-mertk et leurs utilisations
|
|
CN113149982A
(zh)
|
2015-01-20 |
2021-07-23 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
|
AU2016209490B2
(en)
|
2015-01-20 |
2020-09-03 |
Xoc Pharmaceuticals, Inc. |
Isoergoline compounds and uses thereof
|
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
PT3385395T
(pt)
|
2015-08-17 |
2020-05-06 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
|
WO2017040790A1
(fr)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
|
WO2017079566A1
(fr)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CA3006966A1
(fr)
|
2015-12-02 |
2017-06-08 |
Astraea Therapeutics, Llc |
Composes de piperidinyle pour recepteur de nociceptine
|
|
US20190022043A1
(en)
|
2015-12-31 |
2019-01-24 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
DK3399978T3
(da)
|
2016-01-08 |
2020-11-16 |
Celgene Corp |
Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
|
|
MX390772B
(es)
|
2016-01-08 |
2025-03-21 |
Celgene Corp |
Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
|
|
US10189808B2
(en)
|
2016-01-08 |
2019-01-29 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
WO2017151836A1
(fr)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
Prostaglandine-éthanolamides de série j utilisés comme nouveaux agents thérapeutiques pour des troubles de la peau et/ou bucco-dentaires
|
|
JP2019510085A
(ja)
|
2016-03-08 |
2019-04-11 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
癌治療のためのナノ粒子ならびに方法および化合物
|
|
JP2019513151A
(ja)
|
2016-03-08 |
2019-05-23 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
カンプトテシン誘導体及びその使用
|
|
WO2017180794A1
(fr)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
|
|
WO2017184968A1
(fr)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
|
|
EP4190357A1
(fr)
|
2016-05-13 |
2023-06-07 |
Institut Pasteur |
Inhibition de recepteurs nicotiniques beta-2 de l'acetylcholine pour traiter la pathologie de la maladie d'alzheimer
|
|
CA3024508A1
(fr)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anticorps anti-tim-3 et leurs methodes d'utilisation
|
|
CA3030099A1
(fr)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anticorps anti-apoc3 et leurs methodes d'utilisation
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
TWI773694B
(zh)
|
2016-10-11 |
2022-08-11 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
US11124839B2
(en)
|
2016-11-03 |
2021-09-21 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
AU2017353939B2
(en)
|
2016-11-07 |
2025-01-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
WO2018089692A1
(fr)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Dérivés d'eckol, procédés de synthèse et utilisations associées
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
MA50948A
(fr)
|
2016-12-07 |
2020-10-14 |
Agenus Inc |
Anticorps et procédés d'utilisation de ceux-ci
|
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
AU2018225566B2
(en)
|
2017-02-21 |
2019-11-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US12226464B2
(en)
|
2017-04-10 |
2025-02-18 |
Curemark, Llc |
Compositions for treating addiction
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ＡｐｏＣ３抗体およびその使用方法
|
|
WO2018204363A1
(fr)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
EP3630758A1
(fr)
|
2017-06-01 |
2020-04-08 |
Xoc Pharmaceuticals, Inc |
Dérivés d'ergoline destinés à être utilisés en médecine
|
|
SG10202110500TA
(en)
|
2017-06-22 |
2021-11-29 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
|
JP2020525459A
(ja)
|
2017-06-26 |
2020-08-27 |
アンスティテュ・パストゥール |
Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
|
|
WO2019003162A1
(fr)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, membre a5, pour le traitement du glaucome
|
|
CN111315774B
(zh)
|
2017-06-27 |
2023-12-22 |
纽洛可科学有限公司 |
抗fam19a5抗体及其用途
|
|
WO2019003164A1
(fr)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
|
|
CN111344011B
(zh)
|
2017-06-27 |
2024-01-26 |
纽洛可科学有限公司 |
抗fam19a5抗体用于治疗纤维化的用途
|
|
CA3069523A1
(fr)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Souches bacteriennes immunostimulatrices modifiees et utilisations
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US11291663B2
(en)
|
2017-08-07 |
2022-04-05 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US11571401B2
(en)
|
2017-09-01 |
2023-02-07 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
|
CN118995907A
(zh)
|
2017-10-02 |
2024-11-22 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
|
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
|
US20190216751A1
(en)
|
2017-11-15 |
2019-07-18 |
California State University Northridge |
Compositions and Methods for the Treatment and Prevention of Cancer
|
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
|
EP3823986A4
(fr)
|
2018-04-24 |
2022-03-23 |
Neuracle Science Co., Ltd |
Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, élément a5, pour le traitement de la douleur neuropathique
|
|
CA3098807A1
(fr)
|
2018-05-08 |
2019-11-14 |
Neuracle Science Co., Ltd. |
Administration de virus adeno-associe (aav) d'anticorps anti-fam19a5
|
|
CN112119091B
(zh)
|
2018-05-10 |
2025-01-03 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
WO2019222435A1
(fr)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère
|
|
EP3814327A1
(fr)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
|
|
EP3820992A2
(fr)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Souches bactériennes immunostimulatrices modifiées et utilisations associées
|
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
|
EP3844276A2
(fr)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Souches bactériennes immunostimulatrices modifiées et utilisations associées
|
|
WO2020070678A2
(fr)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
|
|
JP7211610B2
(ja)
|
2018-10-16 |
2023-01-24 |
ニューラクル サイエンス カンパニー リミテッド |
抗ｆａｍ１９ａ５抗体の用途
|
|
KR20210098969A
(ko)
|
2018-11-01 |
2021-08-11 |
쿠라 온콜로지, 인크. |
파네실트랜스퍼라제 저해제를 사용한 암의 치료 방법
|
|
JP2022507606A
(ja)
|
2018-11-16 |
2022-01-18 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
|
|
WO2020118042A1
(fr)
|
2018-12-05 |
2020-06-11 |
Jacobs Wagner Christine |
Peptidoglycane de borrelia burgdorferi en tant qu'agent diagnostique et cible pour une intervention thérapeutique dans des pathologies associées à la maladie de lyme
|
|
US12391705B2
(en)
|
2018-12-19 |
2025-08-19 |
Shy Therapeutics, Llc |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2020128033A1
(fr)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Métabolisme cellulaire de l'ensemencement d'un réservoir de vih-1 dans des lymphocytes t cd4+
|
|
KR20210106513A
(ko)
|
2018-12-21 |
2021-08-30 |
쿠라 온콜로지, 인크. |
편평 세포 암종을 위한 요법
|
|
WO2020136603A1
(fr)
|
2018-12-27 |
2020-07-02 |
Neuracle Science Co., Ltd. |
Utilisation d'anticorps anti-fam19a5 pour le traitement de l'athérosclérose
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
MX2021007843A
(es)
|
2018-12-28 |
2021-08-11 |
Vertex Pharma |
Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
|
|
CN113195533B
(zh)
|
2019-01-02 |
2024-04-26 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
EP3921038A1
(fr)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Modulateurs d'il-17a et leurs utilisations
|
|
CN113874081A
(zh)
|
2019-02-26 |
2021-12-31 |
茵思博纳公司 |
高-亲和力抗-mertk抗体及其用途
|
|
WO2020176809A1
(fr)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Bactéries immunostimulatrices modifiées en vue de coloniser des tumeurs, des cellules immunitaires résidant dans une tumeur et le microenvironnement tumoral
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
PL3935042T3
(pl)
|
2019-03-07 |
2024-11-04 |
Nobo Medicine Inc. |
Inhibitory kaspazy i sposoby ich zastosowania
|
|
WO2020190604A1
(fr)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
|
CA3134825A1
(fr)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Procedes de traitement de carcinomes squameux par des inhibiteurs de farnesyltransferase
|
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
|
JP2022529341A
(ja)
|
2019-04-19 |
2022-06-21 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
化合物の結晶形、および化合物の結晶形を生成する方法
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
CN120758062A
(zh)
|
2019-05-20 |
2025-10-10 |
尼尔瓦纳科学股份有限公司 |
窄发射染料、包含其的组合物以及制备和使用其的方法
|
|
CN119752217A
(zh)
|
2019-05-20 |
2025-04-04 |
尼尔瓦纳科学股份有限公司 |
窄发射染料、包含其的组合物以及制备和使用其的方法
|
|
MX2022002315A
(es)
|
2019-08-30 |
2022-03-25 |
Agenus Inc |
Anticuerpos anti-cd96 y sus metodos de uso.
|
|
WO2021055376A1
(fr)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Modulateurs d'il-17a et leurs utilisations
|
|
CA3161450A1
(fr)
|
2019-11-12 |
2021-05-20 |
Actym Therapeutics, Inc. |
Plateformes d'administration de bacteries immunostimulatrices et leur utilisation pour l'administration de produits therapeutiques
|
|
IL294663A
(en)
|
2020-01-13 |
2022-09-01 |
Neoimmunetech Inc |
Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
|
|
JP2023512657A
(ja)
|
2020-02-05 |
2023-03-28 |
ワシントン・ユニバーシティ |
Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
|
|
WO2021257828A1
(fr)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Thiénopyrimidines qui interagissent avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et d'une maladie fibreuse
|
|
EP4149471A4
(fr)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences, Inc. |
Dérivés d'isoquinoléine, leurs procédés de synthèse et leurs utilisations
|
|
MX2023001782A
(es)
|
2020-08-12 |
2023-05-22 |
Actym Therapeutics Inc |
Vacunas, productos terapéuticos y plataformas de administración de arn a base de bacterias inmunoestimuladoras.
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
WO2022094475A1
(fr)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Utilisation de l'interleukine-7 pour le traitement du coronavirus
|
|
JP2023549112A
(ja)
|
2020-11-05 |
2023-11-22 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
MX2023010545A
(es)
|
2021-03-10 |
2023-11-24 |
Dice Molecules Sv Inc |
Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
|
|
WO2022226166A1
(fr)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
|
|
EP4347568A1
(fr)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Hétéroaryl-diamides activateurs d'ire1/xbp1s
|
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗ｉｌ－９抗体及びその使用方法
|
|
CA3236150A1
(fr)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Nouveaux agents therapeutiques antiviraux pan-respiratoires a petites molecules ciblant l'hote
|
|
KR20240115979A
(ko)
|
2021-11-08 |
2024-07-26 |
프로젠토스 테라퓨틱스, 인크. |
혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
|
|
CN119836296A
(zh)
|
2021-12-30 |
2025-04-15 |
新免疫技术有限公司 |
用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
|
|
WO2023129577A1
(fr)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Promédicaments à base de thiol cyclique
|
|
WO2023129576A2
(fr)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Promedicaments thiol acycliques
|
|
US12168673B2
(en)
|
2022-03-02 |
2024-12-17 |
Mitopower, Inc. |
Prodrugs derived from nicotinic acid and ribose
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
AR129053A1
(es)
|
2022-04-14 |
2024-07-10 |
Bristol Myers Squibb Co |
Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
|
|
WO2023198757A1
(fr)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsine pour le traitement d'infections à paramyxoviridae ou orthomyxoviridae
|
|
US20240209100A1
(en)
|
2022-10-21 |
2024-06-27 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
WO2024092043A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridine contenant un spirocycle
|
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
|
EP4608838A1
(fr)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Composés de pyridone contenant un spirocycle
|
|
KR20250089492A
(ko)
|
2022-11-07 |
2025-06-18 |
네오이뮨텍, 인코퍼레이티드 |
비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
|
|
EP4626865A1
(fr)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Activateurs de ire1/xbp1 diamide de pyrazole cyclique
|
|
WO2024118801A1
(fr)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(fr)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anticorps anti-phosphocholine et leurs procédés d'utilisation
|
|
AU2024252640A1
(en)
|
2023-04-07 |
2025-10-02 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
WO2024211807A1
(fr)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Anticorps bispécifiques à charnière modifiée
|
|
WO2024226471A2
(fr)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions et méthodes de traitement de troubles liés à stxbp1
|
|
AU2024269869A1
(en)
|
2023-05-09 |
2025-10-16 |
Progentos Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
|
US20250019450A1
(en)
|
2023-05-19 |
2025-01-16 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to il12 receptor
|
|
WO2025010272A1
(fr)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Molécules fc hétérodimères et leurs utilisations
|
|
WO2025049818A1
(fr)
|
2023-08-29 |
2025-03-06 |
Enosi Therapeutics Corporation |
Antagonistes tnfr1 dépourvus d'activité agoniste et leurs utilisations
|
|
US20250101101A1
(en)
|
2023-09-01 |
2025-03-27 |
iTeos Belgium SA |
Anti-trem2 antibodies and methods of use
|
|
WO2025063888A1
(fr)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Composés ciblant la survivine
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025085416A1
(fr)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Composés gspt1 et procédés d'utilisation des composés
|
|
WO2025090519A1
(fr)
|
2023-10-23 |
2025-05-01 |
Diagonal Therapeutics Inc. |
Anticorps agonistes hétéromériques dirigés contre le récepteur de l'il-18
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025133707A1
(fr)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anticorps anti-tdp-43 et leurs utilisations
|
|
WO2025147691A1
(fr)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions et procédés de dégradation de protéine de translocation nucléaire de récepteur d'hydrocarbure aryle
|
|
WO2025179161A1
(fr)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Composés de dégradation de protéines
|
|
WO2025201633A1
(fr)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
Agent pour réduire la formation d'amyloïdes
|
|
WO2025255341A1
(fr)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Activateurs de tétrahydrofuranyle ire1/xbp1s
|